e0655 The effect of intravenous administration of tirofiban on myocardial reflow and left ventricular remodelling during PCI in patients with acute myocardial infarction

Objective To investigate the efficacy and safety of platelet glycoprotein IIb/IIIa inhibition (tirofiban) during PCI in AMI patients performed primary PCI. Methods A total of 96 patients with AMI were randomised to divide into two groups: the tirofiban group (TG, n=44,) and the control group (CG, n=52). Tirofiban was only administrated in the tirofiban group. Before the CAG, enough clopidogrel, aspirin and heparin be used in both groups. The MACE and the haemorrhage events were collected in each group during in-hospital. The lesion and reperfusion of the IRA and myocardial were analyses by QCA and TMPG. The platelet aggregation rate were recorded All patients received UCG 1 week and 24 weeks after PCI to evaluate the heart function. Results There was no significant differences in age, gender, risk factors, pre-angina, the location of the AMI, heart function, and the mean interval from onset to PCI between the two groups. A greater percentage of TIMI 1 flow of IRA was achieved in TG compared with the control group before PCI (p Conclusion Intravenous administration of trofiban can inhibit the platelet aggregation, improve the coronary flow of IRA, decrease the incidence of NRP in AMI patients performed PCI, which in turn will improve the heart function and decrease the incidence of MACE. Tirofiban can make more IRA patent before PCI, but do not increase the haemorrhage events.